Literature DB >> 33745366

Compression treatment in acute symptomatic proximal deep venous thrombosis - Results of a worldwide survey.

Daniel Rabe1, Hugo Partsch2, Gerhard Heidl3, Mirko Hirschl4, Michael Kundi5, Eberhard Rabe6, Felizitas Pannier7.   

Abstract

OBJECTIVES: The aim of this study was to illustrate how compression is performed worldwide in proximal DVT and if compression management has changed recently.
METHODS: A global online survey, consisting of 36 questions, was used. The survey was solicited from membership lists of Union Internationale de Phlébologie (UIP) membership societies. For differences between the continents in comparison to Western Europe odds ratios and 95% Confidence Intervals (95%CI) where calculated.
RESULTS: We received 626 answers from 41 countries. Compression is routinely used in proximal DVT in all regions (82.8%). 81.4% start compression immediately after diagnosis. In the acute phase of DVT reduction of pain and swelling (91.7%) and PTS prevention (66.2%) are the main reasons for compression. 33.2% recently changed their compression management with 43.5% starting compression earlier and 7.0% later.
CONCLUSIONS: Compression is still used routinely in proximal DVT in addition to anticoagulation. The changes in international guidelines towards the non-routine use of compression in proximal DVT have not caused significant changes in DVT management.

Entities:  

Keywords:  Deep venous thrombosis; compression; post-thrombotic syndrome; symptoms; treatment

Year:  2021        PMID: 33745366     DOI: 10.1177/02683555211003801

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  1 in total

1.  Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Martin H Prins; Sabina Villalta; Raffaele Pesavento; Daniela Tormene; Franco Noventa; Gualtiero Palareti
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.